In conclusion, the current study supports a role for reduced mGluR5 expression in the underlying pathophysiology of FXS in humans; it holds promise as a potential biomarker for use in clinical trials of FXS that could prove critical in improving pharmacological interventions. The gene discussed is GRM5; the disease is fragile X syndrome.